ANALYSIS OF THE EFFICACY AND SAFETY OF DIRECT ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Abstract
Chronic obstructive pulmonary disease (COPD) and atrial fibrillation (AF) are two widely prevalent conditions that often occur in patients over 60 years of age. These diseases have serious health consequences, increasing the risk of complications and worsening the quality of life of patients. Recent scientific studies indicate the adverse prognostic significance of AF in patients with COPD, requiring a comprehensive approach to diagnosis and treatment. For a long time, warfarin was the only oral anticoagulant for the prevention of thromboembolic complications and remains one of the main drugs to this day. Direct oral anticoagulants—rivaroxaban, apixaban, and dabigatran—have expanded the clinical arsenal for stroke prevention in atrial fibrillation. Our study showed that rivaroxaban is non-inferior to warfarin in clinical efficacy and superior warfarin in safety.
References
1. Müllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular Comorbidity in COPD. Chest. 2013;144(4):1163–78. DOI: 10.1378/chest.12 2847.
2. Глова С.Е., Разумовский И.В. Хроническая обструктивная болезнь легких и фибрилляция предсердий. Южно-Российский журнал терапевтической практики. 2021;2(4):22-29.
3. Скворцов В.В., Разваляева О.В., Самохвалова П.Д. Место и роль ривароксабана у пациентов с фибрилляцией предсердий. Лечебное дело. 2022; 3(4):43-46.
4. Patel M.R., Mahaffey K.W., Garg J. et al. for the ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J. Med. 2011; 365:883-891.
5. Гуляихина Д.Е. Влияние варфарина, гепарина и новых пероральных прямых антикоагулянтов (дабигатрана этексилата, ривароксабана, апиксабана) на уровень факторов свертывания: V, VII, VIII, IX, XII, WF // Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2019;11(1):79-92.
